ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

NCI Management Director Leaving For Case Institute.

October 12, 2001

DCT Board Okays Concepts Of Four New Grant Projects, Four Competitive Contract Delays Chlordane Study

March 9, 1984

GM To Offer Three Awards of $1000,000 Each To Cancer Investigators

September 8, 1978

First Test Of Cooperative Groups’ Willingness To Change Coming In New Colorectal Trials

November 14, 1986

NCI Plans Progress Review In Lymphoma This Year.

March 10, 2000

DCE Board Approves Epidemiology Contract Recompetitions

March 17, 1995